Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Cold Spring Harbor Perspectives in Medicine
|
June 29, 2026
New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines
Cristina Donini, Richard K Amewu, Benoit Bestgen, et al.
Journal of Labelled Compounds & Radiopharmaceuticals
|
September 21, 2016
Carbon-14 radiolabeling and tissue distribution evaluation of MMV390048
Molahlehi S Sonopo, Adushan Pillay, Kelly Chibale, et al.
Birth Defects Research
|
April 13, 2022
Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
Claudia Demarta-Gatsi, Cristina Donini, James Duffy, et al.
The American Journal of Tropical Medicine and Hygiene
|
December 12, 2022
Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria
Rezika Mohammed, Mezgebu Silamsaw Asres, Esayas Kebede Gudina, et al.
British Journal of Clinical Pharmacology
|
January 12, 2020
First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
M Farouk Chughlay, Emilie Rossignol, Cristina Donini, et al.
British Journal of Clinical Pharmacology
|
June 2, 2021
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
Jӧrg Täubel, Ulrike Lorch, Georg Ferber, et al.
Antimicrobial Agents and Chemotherapy
|
January 15, 2020
Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
Phumla Sinxadi, Cristina Donini, Hilary Johnstone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2020
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
James S McCarthy, Cristina Donini, Stephan Chalon, et al.
Malaria Journal
|
October 18, 2024
Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
Myriam El Gaaloul, Andre Marie Tchouatieu, Kassoum Kayentao, et al.
The American Journal of Tropical Medicine and Hygiene
|
February 8, 2021
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
Mohamed Farouk Chughlay, Myriam El Gaaloul, Cristina Donini, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Cold Spring Harbor Perspectives in Medicine
|
June 29, 2026
New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines
Cristina Donini, Richard K Amewu, Benoit Bestgen, et al.
Journal of Labelled Compounds & Radiopharmaceuticals
|
September 21, 2016
Carbon-14 radiolabeling and tissue distribution evaluation of MMV390048
Molahlehi S Sonopo, Adushan Pillay, Kelly Chibale, et al.
Birth Defects Research
|
April 13, 2022
Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
Claudia Demarta-Gatsi, Cristina Donini, James Duffy, et al.
The American Journal of Tropical Medicine and Hygiene
|
December 12, 2022
Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria
Rezika Mohammed, Mezgebu Silamsaw Asres, Esayas Kebede Gudina, et al.
British Journal of Clinical Pharmacology
|
January 12, 2020
First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
M Farouk Chughlay, Emilie Rossignol, Cristina Donini, et al.
British Journal of Clinical Pharmacology
|
June 2, 2021
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
Jӧrg Täubel, Ulrike Lorch, Georg Ferber, et al.
Antimicrobial Agents and Chemotherapy
|
January 15, 2020
Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
Phumla Sinxadi, Cristina Donini, Hilary Johnstone, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 3, 2020
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
James S McCarthy, Cristina Donini, Stephan Chalon, et al.
Malaria Journal
|
October 18, 2024
Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
Myriam El Gaaloul, Andre Marie Tchouatieu, Kassoum Kayentao, et al.
The American Journal of Tropical Medicine and Hygiene
|
February 8, 2021
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
Mohamed Farouk Chughlay, Myriam El Gaaloul, Cristina Donini, et al.
Page
of 2